哈佛生物科学公司近期发布业绩展望,预计在2026财年将实现收入同比正向增长。同时,公司预测其税息折旧及摊销前利润(EBITDA)增长率将达到中高个位数水平。
这一增长预期反映出公司对核心业务发展的信心。通过持续优化运营效率和拓展市场,哈佛生物科学正稳步推进其长期战略目标。
哈佛生物科学公司近期发布业绩展望,预计在2026财年将实现收入同比正向增长。同时,公司预测其税息折旧及摊销前利润(EBITDA)增长率将达到中高个位数水平。
这一增长预期反映出公司对核心业务发展的信心。通过持续优化运营效率和拓展市场,哈佛生物科学正稳步推进其长期战略目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.